Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Global X China Biotech ETF (HKD) (2820.HK)
About this ETF
The Global X China Biotech ETF strives to achieve investment returns that closely mirror the performance of its designated benchmark index, prior to the subtraction of any fees and expenses.
Price
Top 10 holdings
| WUXI APPTEC 603259.SS | 12.88% |
| WUXI BIOLOGICS CAYMAN INC 2269.HK | 10.25% |
| INNOVENT BIOLOGICS INC 1801.HK | 10.05% |
| JIANGSU HENGRUI PHARMACEUT 600276.SS | 9.04% |
| BEONE MEDICINES-ADR ONC | 8.91% |
| AKESO INC 9926.HK | 6.05% |
| SINO BIOPHARMACEUTICAL 1177.HK | 4.67% |
| HANSOH PHARMACEUTICAL GROUP 3692.HK | 3.50% |
| 3SBIO INC 1530.HK | 3.21% |
| SHANGHAI ALLIST PHARMACEUT 688578.SS | 2.98% |
Sector mix
Price chart
Returns
| 1 month | +16.18% |
| 3 months | -4.79% |
| 6 months | -1.85% |
| Year to date | -0.41% |
| 1 year | +6.56% |
| 3 years (ann.) | +5.78% |
| 5 years (ann.) | -13.30% |
| 10 years (ann.) | — |
Risk profile
| Volatility (1y, ann.) | 31.19% |
| Sharpe (1y) | 0.36 |
| Sharpe (3y) | 0.34 |
| Sortino (1y) | 0.66 |
| Max drawdown (1y) | -30.54% |
| Max drawdown (5y) | -71.33% |
| Max drawdown (full) | -73.50% |
| Beta vs S&P 500 (1y) | 0.20 |
| Correlation vs S&P 500 (1y) | 0.08 |
Technical outlook as of 2026-07-13
The Monte Carlo cone is drawn on the price chart above (Forecast overlay); RSI, MACD and the rest of the oscillators live in its indicator panels.
Full holdings
| Constituent | ISIN | Market value | Weight |
|---|---|---|---|
| Loading… | |||
Sector breakdown
Geographic exposure
Cost vs. peers
Comparison universe: 6,948 funds of the same asset class.
Cost impact calculator
Dividend history
Accumulating share class Income is reinvested inside the fund instead of being paid out. (inferred from the absence of distributions)
No distributions on record — accumulating share classes reinvest income instead of paying it out.
ESG profile
No ESG estimate available: none of the scored universe overlaps this portfolio (typical for bond, commodity or synthetic funds).
Scored coverage: 0.0% of the portfolio by weight.
Similar ETFs
| Fund | TER | AUM (USD) | Yield (TTM) | Return 1y | Sharpe 1y |
|---|---|---|---|---|---|
| Vanguard Total Stock Market ETF VTI | 0.03% | 2.30T | 1.05% | +19.93% | 1.48 |
| Vanguard S&P 500 ETF VOO | 0.03% | 1.70T | 1.07% | +19.68% | 1.49 |
| iShares Core S&P 500 ETF IVV | 0.03% | 894.38B | 1.09% | +19.68% | 1.49 |
| State Street SPDR S&P 500 ETF SPY | 0.09% | 789.23B | 1.00% | +19.71% | 1.49 |
| SPDR S&P 500 ETF Trust 1557.T | 0.09% | 789.09B | 0.49% | +37.54% | 2.26 |
| State Street SPDR S&P 500 ETF SPY.AX | 0.09% | 788.13B | 1.00% | +11.84% | 1.13 |
| Vanguard Total International Stock ETF VXUS | 0.05% | 652.30B | 2.61% | +20.58% | 1.21 |
| Invesco QQQ Trust, Series 1 QQQ | 0.18% | 481.14B | 0.43% | +28.14% | 1.43 |
| Vanguard Growth ETF VUG | 0.03% | 393.80B | 0.39% | +16.85% | 0.99 |
| Vanguard FTSE Developed Markets ETF VEA | 0.03% | 317.30B | 2.60% | +21.64% | 1.23 |
Cheaper alternatives
No fund of the class reaches 60% portfolio overlap — showing the cheapest funds of the class instead.
| Fund | TER | AUM (USD) | Overlap |
|---|---|---|---|
| Vanguard FTSE Emerging Markets ETF VWO | 0.06% | 162.80B | 0.6% |
| iShares Core MSCI Emerging Markets ETF IEMG | 0.09% | 156.92B | 0.5% |
| Vanguard Total International Stock ETF VXUS | 0.05% | 652.30B | 0.2% |
| State Street SPDR Portfolio S&P 500 ETF SPYM | 0.02% | 159.32B | 0.0% |
| iShares Core S&P 500 ETF IVV | 0.03% | 894.38B | 0.0% |
